Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies

Joanna Bogusławska-Duch; Magdalena Ducher-Hanaka; Agnieszka Zajkowska; Milena Czajka; Maciej Małecki

doi:10.5114/ada.2021.110461

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2021
vol. 38

Send email

Copy url:

abstract:

Original paper

Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies

Joanna Bogusławska-Duch

¹

,

Magdalena Ducher-Hanaka

¹

,

Agnieszka Zajkowska

¹

,

Milena Czajka

¹

,

Maciej Małecki

¹

Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland

Adv Dermatol Allergol 2021; XXXVIII (5): 887–898

DOI: https://doi.org/10.5114/ada.2021.110461

Online publish date: 2021/11/05

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Bogusławska-Duch J, Ducher-Hanaka M, Zajkowska A, Czajka M, Małecki M. Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2021;38(5):887-898. doi:10.5114/ada.2021.110461.

APA

Bogusławska-Duch, J., Ducher-Hanaka, M., Zajkowska, A., Czajka, M.,  & Małecki, M. (2021). Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 38(5), 887-898. https://doi.org/10.5114/ada.2021.110461

Chicago

Bogusławska-Duch, Joanna, Magdalena Ducher-Hanaka, Agnieszka Zajkowska, Milena Czajka,  and Maciej Małecki. 2021. "Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 38 (5): 887-898. doi:10.5114/ada.2021.110461.

Harvard

Bogusławska-Duch, J., Ducher-Hanaka, M., Zajkowska, A., Czajka, M.,  and Małecki, M. (2021). Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 38(5), pp.887-898. https://doi.org/10.5114/ada.2021.110461

MLA

Bogusławska-Duch, Joanna et al. "Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 38, no. 5, 2021, pp. 887-898. doi:10.5114/ada.2021.110461.

Vancouver

Bogusławska-Duch J, Ducher-Hanaka M, Zajkowska A, Czajka M, Małecki M. Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2021;38(5):887-898. doi:10.5114/ada.2021.110461.

Introduction
Gene therapy is an innovative form of treatment of genetic diseases, in which psiRNA molecules silencing specific genes are applied. Aim: The study evaluated the anti-tumour effect of psiRNA silencing preparations of the vascular endothelial growth factor (VEGF) and Sry-related HMG-Box gene 10 (SOX10) on melanoma (B16-F10) by inhibiting angiogenesis.

Material and methods
The preparations based on plasmid vectors psiRNA silencing the gene SOX10 and VEGF that form complexes with cationic lipid (psiRNA/carrier) have been developed. psiRNA preparations were tested on the mouse melanoma cell line B16-F10, both in vitro and in vivo. The silencing activity of transfected melanoma cells with the obtained psiRNA preparations was examined using the qPCR and Western blot methods. The anti-tumour activity of psiRNA preparations on melanoma tumour cells was then evaluated in a mouse in vivo model.

Results
In vitro studies have shown that the B16-F10 cells efficiently transfect non-viral preparations – psiRNA: Lyovec (74–89%). Worth mentioning is the fact that silencing SOX10 in B16-F10 melanoma cells increases the expression of the COL18A1 gene (compared to the preparation inhibiting only VEGF), which codes the endostatin to stop angiogenesis. In vivo results show that the level of haemoglobin in tumours of mice treated with psiRNA formulations was over 6 times lower than controls and tumour mass was 60-80% lower.

Conclusions
The novel study proves that simultaneous inhibition of SOX10 and VEGF enhances the antiangiogenic action and thus contributes to a significant halt of disease development. In addition, these data expand knowledge about SOX10 regulation and functions.

keywords:

Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10 – in vitro and in vivo studies

Joanna Bogusławska-Duch 1 , Magdalena Ducher-Hanaka 1 , Agnieszka Zajkowska 1 , Milena Czajka 1 , Maciej Małecki 1

cancer, melanoma, vascular endothelial growth factor, Sry-related HMG-Box gene 10, gene therapy, angiogenesis

Joanna Bogusławska-Duch

¹

,

Magdalena Ducher-Hanaka

¹

,

Agnieszka Zajkowska

¹

,

Milena Czajka

¹

,

Maciej Małecki

¹